Antibody-directed therapy: Past, present, and future

被引：41

作者：

Gelfand, EW ^{[1
]}

机构：

[1] Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2001年 / 108卷 / 04期

关键词：

anti-inflammatory; autoimmunity; monoclonal antibody; polyclonal antibody; hyperimmune Igs; immunomodulation;

D O I：

10.1067/mai.2001.117824

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Antibody-based therapy, which is the administration of polyclonal, hyperimmune, or monoclonal antibodies, has emerged as an important therapeutic approach in a wide variety of diseases. Polyclonal intravenous immunoglobulin became available in the early 1980s and supplanted intramuscular IgG in the treatment of antibody-deficiency diseases. During the last 2 decades, intravenous immunoglobulin has shown potent immunomodulatory and anti-inflammatory effects in many diseases. Whether these effects are mediated through specific antibody or Fc-receptor interactions is unclear. This review examines some of the current and future prospects for antibody-based therapy.

引用

页码：S111 / S116

页数：6

共 56 条

[1]

Achiron A, 1999, NEUROLOGY, V52, P214

[2] Prophylaxis for respiratory syncytial, virus with respiratory syncytial virus-immune globulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost [J].

Atkins, JT ;

Karimi, P ;

Morris, BH ;

McDavid, G ;

Shim, S .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (02) :138-143

[3]

AUKRUST P, 1994, BLOOD, V84, P2136

[4] INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN PATIENTS WITH MOTOR-NEURON SYNDROMES ASSOCIATED WITH ANTI-GM1 ANTIBODIES - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].

AZULAY, JP ;

BLIN, O ;

POUGET, J ;

BOUCRAUT, J ;

BILLETURC, F ;

CARLES, G ;

SERRATRICE, G .

NEUROLOGY, 1994, 44 (03) :429-432

[5] Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome [J].

Bain, PG ;

Motomura, M ;

NewsomDavis, J ;

Misbah, SA ;

Chapel, HM ;

Lee, ML ;

Vincent, A ;

Lang, B .

NEUROLOGY, 1996, 47 (03) :678-683

[6] INTRAVENOUS IMMUNOGLOBULIN THERAPY FOR TOXIC SHOCK SYNDROME [J].

BARRY, W ;

HUDGINS, L ;

DONTA, ST ;

PESANTI, EL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (24) :3315-3316

[7] High-avidity autoantibodies to cytokines [J].

Bendtzen, K ;

Hansen, MB ;

Ross, C ;

Svenson, M .

IMMUNOLOGY TODAY, 1998, 19 (05) :209-211

[8] Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome [J].

Bril, V ;

Ilse, WK ;

Pearce, R ;

Dhanani, A ;

Sutton, D ;

Kong, K .

NEUROLOGY, 1996, 46 (01) :100-103

[9] A CONTROLLED TRIAL OF HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN INFUSIONS AS TREATMENT FOR DERMATOMYOSITIS [J].

DALAKAS, MC ;

ILLA, I ;

DAMBROSIA, JM ;

SOUEIDAN, SA ;

STEIN, DP ;

OTERO, C ;

DINSMORE, ST ;

MCCROSKY, S .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (27) :1993-2000

[10] Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:: Results of a phase II trial of rituximab [J].

Davis, TA ;

White, CA ;

Grillo-López, AJ ;

Velásquez, WS ;

Link, B ;

Maloney, DG ;

Dillman, RO ;

Williams, ME ;

Mohrbacher, A ;

Weaver, R ;

Dowden, S ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1851-1857

← 1 2 3 4 5 6 →